title: Ampelopsin reduces the migration and invasion of ovarian cancer cells via inhibition of epithelial-to-mesenchymal transition.
abstract: Ampelopsin has displayed anticancer activity in several types of cancers. However, no evidence has been reported for the direct effect of ampelopsin on ovarian cancer cell migration and invasion, and the underling mechanisms have not yet been clearly established. The aim of the present study was to investigate the influence of ampelopsin on the migration and invasion of ovarian cancer. Proliferation and viability of the ovarian cancer cells were detected by MTT assay. Migration and invasion of the cells were detected, respectively, by scratch wound healing assay and Transwell assay. The expression levels of epithelial-to-mesenchymal transition (EMT) markers were detected at the protein level after stimulation with ampelopsin. Then, the expression levels of NF-κB and p-IκBα were detected with western blot analysis. Meanwhile, an inhibitor of NF-κB was used to investigate the effect of ampelopsin. Finally, the expression of Snail was also detected. Proliferation, migration and invasion of the A2780 cells were all inhibited following the application of ampelopsin. Ampelopsin upregulated E-cadherin and downregulated N-cadherin and vimentin in a concentration- and time-dependent manner. Ampelopsin also exerted its ability to suppress the nuclear translocation of the NF-κB pathway. Administration of the inhibitor BAY11-7082 confirmed the roles of NF-κB in the expression of EMT markers and its transcription factor. These results demonstrated that ampelopsin inhibited EMT and reduced the invasion of ovarian cancer cells via the NF-κB/Snail pathway.
authors.affiliation: Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, P.R. China.
authors.forename: Tianfeng
authors.initials: T
authors.lastname: Liu
authors.affiliation: Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, P.R. China.
authors.forename: Peishu
authors.initials: P
authors.lastname: Liu
authors.affiliation: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong, P.R. China.
authors.forename: Feng
authors.initials: F
authors.lastname: Ding
authors.affiliation: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong, P.R. China.
authors.forename: Nina
authors.initials: N
authors.lastname: Yu
authors.affiliation: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong, P.R. China.
authors.forename: Shihong
authors.initials: S
authors.lastname: Li
authors.affiliation: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong, P.R. China.
authors.forename: Surong
authors.initials: S
authors.lastname: Wang
authors.affiliation: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong, P.R. China.
authors.forename: Xiaofei
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong, P.R. China.
authors.forename: Xiangxiu
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Gynecology, Linyi People's Hospital, Linyi, Shandong, P.R. China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Cardiology, Central Hospital of Zibo, Zibo, Shandong, P.R. China.
authors.forename: Yunhe
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Cardiology, Central Hospital of Zibo, Zibo, Shandong, P.R. China.
authors.forename: Bo
authors.initials: B
authors.lastname: Li
mesh_terms: D021581:Active Transport, Cell Nucleus; D000970:Antineoplastic Agents / Q000494:pharmacology; D015820:Cadherins / Q000378:metabolism; D045744:Cell Line, Tumor / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation; D002470:Cell Survival; D015536:Down-Regulation; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects*; D005260:Female; D005419:Flavonoids / Q000494:pharmacology*; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism; D009362:Neoplasm Metastasis; D009570:Nitriles / Q000737:chemistry; D010051:Ovarian Neoplasms / Q000378:metabolism*; D013450:Sulfones / Q000737:chemistry; D013997:Time Factors; D015854:Up-Regulation; D014746:Vimentin / Q000378:metabolism
chemical_list: C434003:3-(4-methylphenylsulfonyl)-2-propenenitrile; D000970:Antineoplastic Agents; D015820:Cadherins; D005419:Flavonoids; D020672:I-kappa B Proteins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; D009570:Nitriles; D013450:Sulfones; D014746:Vimentin; D000072000:NF-KappaB Inhibitor alpha; C106407:ampelopsin